Stocks to watch for October 26, 2026 include KEC International after ₹2,872 crore of transmission orders, Gland Pharma and Lupin following US regulatory inspections, and Raymond after its board approved a proposed name change. Other corporate announcements cover construction contracts, a shipping acquisition agreement and an antibiotic licensing deal.
Key Takeaways
- KEC secured ₹2,872 crore of PGCIL orders, taking year-to-date order intake above ₹13,500 crore.
- Gland Pharma received four FDA inspection observations and Lupin received one; both plan regulatory responses.
- Raymond's name change remains a proposal, while Orchid Pharma's Latin American commercialization depends on national approvals.
Table of Contents
- Stocks to watch: KEC's transmission orders lead
- Construction contracts and RailTel's letter of intent
- FDA observations put Gland Pharma and Lupin in focus
- Orchid Pharma signs Latin American licensing agreement
- Raymond proposal, Honasa appointment and vessel purchases
- Smaller-company projects and product launches
- Conclusion
Stocks to watch: KEC's transmission orders lead
KEC International's October 24 order announcement covers the design, supply and installation of 765 kV transmission lines for Power Grid Corporation of India, or PGCIL. The turnkey contracts total ₹2,872 crore.
Managing Director and Chief Executive Vimal Kejriwal said the awards include the largest-ever order for KEC's India transmission and distribution business. The projects are associated with evacuating 8.5 GW of renewable energy from Gujarat.
The wins took KEC's year-to-date order intake above ₹13,500 crore, including approximately ₹9,500 crore from transmission and distribution. These figures represent orders secured, rather than revenue already recognized.
| Item | Details |
|---|---|
| Takyon Networks | Received a ₹19.40 crore order from Hindustan Power Exchange for hardware, software and licences. |
| Pro CLB Global | Started BNP Café, a business networking division intended to connect entrepreneurs, professionals, service providers and companies. |
| Lehar Footwears | Received Bureau of Indian Standards licence approval for its Shoes for General Purpose product. |
| Richa Infosystems | Launched the COOL MAXX air-conditioner series under its EARTHONIC consumer brand. |
Construction contracts and RailTel's letter of intent
Ramky Infrastructure signed a contract with Rail Vikas Nigam worth approximately ₹588.57 crore, including GST. The work covers residential towers, a shopping complex and associated infrastructure at the existing NMDC Township in Bacheli, Chhattisgarh. Construction is scheduled for 30 months from the appointed date, followed by a 12-month defect liability period.
B.L. Kashyap and Sons secured a ₹495.86 crore order, excluding GST, from Signature Global. It covers civil structures and part of the mechanical, electrical and plumbing work for four towers and basements, plus residential and commercial ancillary buildings. Execution is expected to take approximately 40 months from site handover.
RailTel received a ₹20.04 crore letter of intent from Munitions India for data centre and disaster recovery facilities on an infrastructure-as-a-service platform. The Q-Shakti project will support 13 locations over six years, with a possible three-year extension. The announcement concerns a letter of intent, distinct from the signed contract disclosed by Ramky.
FDA observations put Gland Pharma and Lupin in focus
The US Food and Drug Administration conducted an unannounced current good manufacturing practice inspection at Gland Pharma's Dundigal formulation facility from October 12 to October 23, 2026. The inspection ended with four Form 483 observations.
Gland Pharma described the observations as procedural, neither repeated nor related to data integrity. The company said it would submit corrective and preventive actions within the stipulated period; that description is the company's assessment.
Lupin separately said an FDA inspection at its Goa manufacturing facility concluded with one Form 483 observation. It plans to address the observation and submit a comprehensive response within the required timeframe.
Orchid Pharma signs Latin American licensing agreement
Orchid Pharma and Libra signed a licensing and supply agreement for Exblifep across nine Latin American markets. The antibiotic combines cefepime and enmetazobactam and is used for specified Gram-negative bacterial infections, including complicated urinary tract infections and hospital-acquired and ventilator-associated bacterial pneumonia.
Commercialization in each covered market remains subject to approval from the relevant national regulator. The agreement therefore establishes a licensing and supply arrangement, rather than confirming immediate launches in all nine markets.
Raymond proposal, Honasa appointment and vessel purchases
Raymond's board approved a proposal to rename the company Raymond Aerospace, Defence & Engineering Ltd. The disclosed development is board approval of a proposal, not a completed name change.
Honasa Consumer elevated Vipul Maheshwari to chief product and technology officer. He will oversee product, technology, engineering and analytics, with a mandate to advance the company's AI-led transformation and agentic AI plans.
Transworld Shipping Lines said its wholly owned subsidiary, Transworld Sea-Connect IFSC, signed a memorandum of agreement with Panama's Orient Express Lines to acquire two container vessels. The agreed consideration is $22.03 million for OEL Surya and $20.75 million for OEL Varun. The announcement describes an acquisition agreement, not completed delivery.
Smaller-company projects and product launches
Melstar Information Technologies' wholly owned subsidiary, Melstarr Aviations Tech, signed a memorandum of understanding with the Andhra Pradesh Economic Development Board for a proposed maintenance training organization at Orvakal in Kurnool district. The plan envisages approximately ₹20 crore of investment on five acres, with roughly 25 direct and 25 indirect jobs.
Other announcements span technology procurement, business networking, footwear certification and consumer appliances. Their disclosed scope is summarized below.
Conclusion
The next stated steps include Gland Pharma's corrective-action submission and Lupin's response to the FDA. For Orchid Pharma, national regulatory approvals remain necessary before commercialization in the markets covered by its new agreement.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
